dalteparin injection
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Venous Thromboembolism
Conditions
Venous Thromboembolism, Pulmonary Embolism
Trial Timeline
Jul 1, 2009 → Dec 1, 2014
NCT ID
NCT00876915About dalteparin injection
dalteparin injection is a phase 3 stage product being developed by Eisai for Venous Thromboembolism. The current trial status is terminated. This product is registered under clinical trial identifier NCT00876915. Target conditions include Venous Thromboembolism, Pulmonary Embolism.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00876915 | Phase 3 | Terminated |
Competing Products
20 competing products in Venous Thromboembolism